608 related items for PubMed ID: 19995846
1. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846
[Abstract] [Full Text] [Related]
2. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G, COGIMUS Study Group.
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[Abstract] [Full Text] [Related]
3. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
4. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 26; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
5. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P, Calabrese M, Biasi G, Gallo P.
J Neurol; 2004 Mar 26; 251(3):305-9. PubMed ID: 15015010
[Abstract] [Full Text] [Related]
6. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C, COGIMUS Study Group.
Mult Scler; 2011 Aug 26; 17(8):991-1001. PubMed ID: 21502310
[Abstract] [Full Text] [Related]
7. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
Mult Scler; 2009 Aug 26; 15(8):965-76. PubMed ID: 19465443
[Abstract] [Full Text] [Related]
8. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP, Italian Multiple Sclerosis Database Network (MSDN) Group.
Ann Neurol; 2009 Oct 26; 66(4):513-20. PubMed ID: 19847899
[Abstract] [Full Text] [Related]
9. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul 26; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
10. New natural history of interferon-beta-treated relapsing multiple sclerosis.
Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.
Ann Neurol; 2007 Apr 26; 61(4):300-6. PubMed ID: 17444502
[Abstract] [Full Text] [Related]
11. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
O'Rourke K, Walsh C, Antonelli G, Hutchinson M.
Mult Scler; 2007 Apr 26; 13(3):336-42. PubMed ID: 17439902
[Abstract] [Full Text] [Related]
12. Measures in the first year of therapy predict the response to interferon beta in MS.
Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X.
Mult Scler; 2009 Jul 26; 15(7):848-53. PubMed ID: 19542263
[Abstract] [Full Text] [Related]
13. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
14. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
Arroyo E, Grau C, Ramo-Tello C, Parra J, Sánchez-Soliño O, GAP Study Group.
Eur Neurol; 2011 Feb 10; 65(2):59-67. PubMed ID: 21212677
[Abstract] [Full Text] [Related]
15. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
[Abstract] [Full Text] [Related]
16. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
Mult Scler; 2008 May 10; 14(4):479-84. PubMed ID: 18562504
[Abstract] [Full Text] [Related]
17. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.
Mult Scler; 2012 Aug 10; 18(8):1125-34. PubMed ID: 22194217
[Abstract] [Full Text] [Related]
18. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
J Neurol Sci; 2010 May 15; 292(1-2):28-35. PubMed ID: 20236661
[Abstract] [Full Text] [Related]
19. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
Bosca I, Villar LM, Coret F, Magraner MJ, Simó-Castelló M, Alvarez-Cermeño JC, Casanova B.
Mult Scler; 2010 Jul 15; 16(7):810-5. PubMed ID: 20538705
[Abstract] [Full Text] [Related]
20. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study.
Russo P, Paolillo A, Caprino L, Bastianello S, Bramanti P.
J Eval Clin Pract; 2004 Nov 15; 10(4):511-8. PubMed ID: 15482413
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
